CF PharmTech, Inc., a Shuzhou, China-based pharmaceutical company, raised $90m in Series E funding.
The round was led by New Alliance Capital with participation from new investors CR-CP Life Science Fund, Finnova Capital, GT Capital, Co-stone Asset Management, Xiangcheng Financial Holdings, Everest Venture Capital, and existing investors, such as Oriza Holdings, Longmen Venture Capital, GTJA Investment and CMB International.
The company intends to use the funds to to bring products in its pipeline to market.
CF PharmTech is a pharmaceutical company dedicated to respiratory health. Since its inception, the company has already established state of the art R&D and manufacturing facilities for inhalation products. Currently, CF It currently has a pipeline of over 20 products that are headed to China and global markets.